[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2508871C - Forme cristalline f de sel d'hemi-calcium d'astorvastatine - Google Patents

Forme cristalline f de sel d'hemi-calcium d'astorvastatine Download PDF

Info

Publication number
CA2508871C
CA2508871C CA002508871A CA2508871A CA2508871C CA 2508871 C CA2508871 C CA 2508871C CA 002508871 A CA002508871 A CA 002508871A CA 2508871 A CA2508871 A CA 2508871A CA 2508871 C CA2508871 C CA 2508871C
Authority
CA
Canada
Prior art keywords
crystalline form
ketone
process according
preparation
phenylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002508871A
Other languages
English (en)
Other versions
CA2508871A1 (fr
Inventor
Fritz Blatter
Martin Szelagiewicz
Paul Adriaan Van Der Schaaf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02406037A external-priority patent/EP1424324A1/fr
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CA2508871A1 publication Critical patent/CA2508871A1/fr
Application granted granted Critical
Publication of CA2508871C publication Critical patent/CA2508871C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La présente invention concerne la forme polymorphe F de calcium d'atorvastatine, des procédés de sa préparation et de compositions pharmaceutiques comportant cette forme cristalline.
CA002508871A 2002-11-28 2003-11-26 Forme cristalline f de sel d'hemi-calcium d'astorvastatine Expired - Fee Related CA2508871C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP02406037A EP1424324A1 (fr) 2002-11-28 2002-11-28 Forme cristalline F de calcium d'atorvastatine
EP02406037.8 2002-11-28
EP03405110.2 2003-02-20
EP03405110 2003-02-20
PCT/US2003/038090 WO2004050618A2 (fr) 2002-11-28 2003-11-26 Forme cristalline

Publications (2)

Publication Number Publication Date
CA2508871A1 CA2508871A1 (fr) 2004-06-17
CA2508871C true CA2508871C (fr) 2008-09-09

Family

ID=32471910

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002508871A Expired - Fee Related CA2508871C (fr) 2002-11-28 2003-11-26 Forme cristalline f de sel d'hemi-calcium d'astorvastatine

Country Status (4)

Country Link
EP (1) EP1572643A2 (fr)
AU (1) AU2003297594A1 (fr)
CA (1) CA2508871C (fr)
WO (1) WO2004050618A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
JP2005519076A (ja) * 2002-02-15 2005-06-30 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンヘミカルシウムの新規結晶形態およびその調製方法ならびにアトルバスタチンヘミカルシウム形態ｉ、ｖｉｉｉおよびｉｘの新規調製方法
HUE029911T2 (en) * 2004-07-16 2017-04-28 Lek Pharmaceuticals Products of atorvastatin calcium oxidative degradation
US8026376B2 (en) 2004-07-20 2011-09-27 Pfizer, Inc. Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoicacid calcium salt (2:1)
JP2007505944A (ja) * 2004-07-22 2007-03-15 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンヘミカルシウム及びその調製の方法
KR100923939B1 (ko) * 2004-09-28 2009-10-29 테바 파마슈티컬 인더스트리즈 리미티드 실질적으로 불순물을 함유하지 않는 아토르바스타틴 칼슘의형태를 제조하는 방법
WO2006048894A1 (fr) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Nouvelles formes cristallines de calcium d'atorvastatine et procedes de fabrication
KR20080007561A (ko) 2005-12-13 2008-01-22 테바 파마슈티컬 인더스트리즈 리미티드 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법
MX2008002804A (es) * 2006-06-28 2008-04-02 Teva Pharma Formas cristalinas de atorvastatina.
CN101657419A (zh) * 2007-03-02 2010-02-24 东亚制药株式会社 吡咯基庚酸衍生物的新晶型
EP2185527A2 (fr) * 2007-07-11 2010-05-19 Actavis Group PTC EHF Nouveau polymorphe d'atorvastatine calcium et son utilisation pour la préparation d'atorvastatine calcium amorphe
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL128862A (en) * 1995-07-17 2007-12-03 Warner Lambert Co [R - (R * R *)] - 2 - (4 - fluorophenyl) - ß, d - dihydroxy - 5 - (1 - methyl - ethyl) 3 - phenyl - 4 - [(phenamino) carbonyl)] - 1H - Pyrol - 1 - Patenoic acid Hydrogen salt Hydrogen crystalline (Atorostatin) Crystalline hydrate
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
CZ20021642A3 (cs) * 1999-11-17 2003-05-14 Teva Pharmaceutical Industries Ltd. Polymorfní formy atorvastatinu vápenatého
AU780247B2 (en) * 1999-12-17 2005-03-10 Pfizer Science And Technology Ireland Limited A process for producing crystalline atorvastatin calcium
IL149087A0 (en) * 1999-12-17 2002-11-10 Warner Lambert Res & Dev Ie A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium
SK6592003A3 (en) * 2000-11-03 2004-01-08 Teva Pharma Atorvastatin hemi-calcium form VII
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2623599A1 (fr) * 2000-12-27 2002-07-04 Paul Adrian Van Der Schaaf Formes cristallines d'atorvastatine
WO2002057229A1 (fr) * 2001-01-19 2002-07-25 Biocon India Limited FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE)
UA74075C2 (en) * 2001-06-29 2005-10-17 Warner Lambert Co NOVEL CRYSTALLINE FORMS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-b, d-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1??-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)(ATORVASTATIN) (VARIANTS)
RU2304139C2 (ru) * 2001-07-30 2007-08-10 Д-р Редди'с Лабораторис Лтд Кристаллические формы vi и vii кальциевой соли аторвастатина
JP2005519076A (ja) * 2002-02-15 2005-06-30 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンヘミカルシウムの新規結晶形態およびその調製方法ならびにアトルバスタチンヘミカルシウム形態ｉ、ｖｉｉｉおよびｉｘの新規調製方法
AU2002330735A1 (en) * 2002-09-03 2004-03-29 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof

Also Published As

Publication number Publication date
WO2004050618A8 (fr) 2005-07-14
CA2508871A1 (fr) 2004-06-17
WO2004050618A3 (fr) 2004-07-15
AU2003297594A8 (en) 2004-06-23
EP1572643A2 (fr) 2005-09-14
WO2004050618A2 (fr) 2004-06-17
AU2003297594A1 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
CA2508871C (fr) Forme cristalline f de sel d'hemi-calcium d'astorvastatine
US7189861B2 (en) Processes for preparing amorphous atorvastatin hemi-calcium
KR100400805B1 (ko) 무정형[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산칼슘염(2:1)의신규제조방법
CA2431068C (fr) Formes cristallines d'atorvastatine
CZ20021642A3 (cs) Polymorfní formy atorvastatinu vápenatého
AU2010340799A1 (en) Darunavir polymorph and process for preparation thereof
US20080269315A1 (en) Crystalline form
WO2003070665A2 (fr) Processus destines a la desolvation des solvates de demi-calcium d'atorvastatine et demi-calcium d'atorvastatine sensiblement exempt de solvant organique
JP2009500429A (ja) 保存後も安定なアトルバスタチンカルシウムの結晶形
EP3471734B1 (fr) Formes à l'état solide de citrate d'ixazomib
CA2672554C (fr) Nouvelles formes de [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(isopropyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoatede calcium (2:1)
HU227124B1 (en) Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
WO2012015157A1 (fr) Nouvelle forme cristalline du sel d'hémicalcium de l'atorvastatine, son hydrate et son procédé de production
MX2008000375A (en) Crystalline form of atorvastatin calcium stable after storage
AU2007205725A1 (en) Novel cyrstal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2009139730A1 (fr) Fabrication de nouvelles formes non cristallines d'atorvastatine calcique
ZA200303976B (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed